|本期目录/Table of Contents|

 WANG Mengyue,LI Teng,JIANG Shuguang,et al.Recent advances in liposome-based co-delivery systems for combination cancer therapy[J].Chinese Journal of Bioprocess Engineering,2018,16(05):33-41.[doi:10.3969/j.issn.1672-3678.2018.05.005]





Recent advances in liposome-based co-delivery systems for combination cancer therapy
中国药科大学 高端药物制剂与材料研究中心,江苏 南京 210009
WANG MengyueLI TengJIANG ShuguangMO Ran
Center of Advanced Pharmaceuticals and Biomaterials,China Pharmaceutical University,Nanjing 210009,China
脂质体 共递药系统 联合治疗 癌症 生物材料


[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2] KE X,SHEN L S.Molecular targeted therapy of cancer:the progress and future prospect[J].Front Lab Med,2017,1(2):69-75.
[3] CHAN C W H,TSUI S K W,LAW B M H,et al.The utilization of the immune system in lung cancer treatment:beyond chemotherapy[J].Int J Mol Sci,2016,17(3):286.
[4] MA J L,HENNESSEY D B,NEWELL B P,et al.Radiotherapy-related complications presenting to a urology department:a more common problem than previously thought[J].BJU Int,2018,121(S3):28-32.
[5] XU X,HO W,ZHANG X,et al.Cancer nanomedicine:from targeted delivery to combination therapy[J].Trends Mol Med,2015,21(4):223-232.
[6] SHI J J,KANTOFF P W,WOOSTER R,et al.Cancer nanomedicine:progress,challenges and opportunities[J].Nat Rev Cancer,2017,17(1):20-37.
[7] PATTNI B S,CHUPIN V V,TORCHILIN V P.New developments in liposomal drug delivery[J].Chem Rev,2015,115(19):10938-10966.
[8] KIM Y J,LIU Y,LI S,et al.Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment[J].Mol Pharm,2015,12(8):2811-2822.
[9] PARK J,WRZESINSKI S H,STERN E,et al.Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy[J].Nat Mater,2012,11(10):895-905.
[10] BANGHAM A D.A correlation between surface charge and coagulant action of phospholipids[J].Nature,1961,192:1197-1198.
[11] BANGHAM A D,REES K R,SHOTLANDER V.Penetration of lipid films by compounds preventing liver necrosis in rats[J].Nature,1962,193:754-756.
[12] BANGHAM A D,STANDISH M M,WATKINS J C.Diffusion of univalent ions across the lamellae of swollen phospholipids[J].J Mol Biol,1965,13(1):238-252.
[13] GREGORIADIS G,RYMAN B E.Lysosomal localization of β-fructofuranosidase-containing liposomes injected into rats[J].Biochem J,1972,129(1):123-133.
[14] ZOU Y,XIA Y,ZHANG J,et al.GE11-directed functional polymersomal doxorubicin as an advanced alternative to clinical liposomal formulation for ovarian cancer treatment[J].Mol Pharm,2018,DOI:10.1021/acs.molpharmaceut.8b00024.
[15] CARACCIOLO G.Clinically approved liposomal nanomedicines:lessons learned from the biomolecular corona[J].Nanoscale,2018,10(9):4167-4172.
[16] JOHNSEN K B,GUDBERGSSON J M,DUROUX M,et al.On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems:a commentary[J].J Control Release,2018,269(10):10-14.
[17] SLINGERLAND M,GUCHELAAR H J,GELDERBLOM H.Liposomal drug formulations in cancer therapy:15 years along the road[J].Drug Discov Today,2012,17(3/4):160-166.
[18] MU L M,JU R J,LIU R,et al.Dual-functional drug liposomes in treatment of resistant cancers[J].Adv Drug Deliv Rev,2017,115(1):46-56.
[19] 左勇亮,肖人钟,王蓉蓉.主动靶向脂质体研究进展[J].中国现代应用药学,2013,30(10):1151-1156.
[20] ZYLBERBERG C,GASKILL K,PASLEY S,et al.Engineering liposomal nanoparticles for targeted gene therapy[J].Gene Ther,2017,24(8):441-452.
[21] YUNG B C,LI J,ZHANG M,et al.Lipid nanoparticles composed of quaternary amine-tertiary amine cationic lipid combination(QTsome)for therapeutic delivery of AntimiR-21 for lung cancer[J].Mol Pharm,2016,13(2):653-662.
[22] FELGNER P L,GADEK T R,HOLM M,et al.Lipofection:a highly efficient,lipid-mediated DNA-transfection procedure[J].Proc Natl Acad Sci USA,1987,84(21):7413-7417.
[23] STRIETH S,EICHHORN M E,WERNER A,et al.Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin[J].Clin Cancer Res,2008,14(14):4603-4611.
[24] GALANIS E,BURCH P A,RICHARDSON R L,et al.Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J].Cancer,2004,101(11):2557-2566.
[25] SHUKLA S,HALDORAI Y,HWANG S K,et al.Current demands for food-approved liposome nanoparticles in food and safety sector[J].Front Microbiol,2017,8:2398.
[26] BATIST G,GELMON K A,CHI K N,et al.Safety,pharmacokinetics,and efficacy of CPX-1 liposome injection in patientswith advanced solid tumors[J].Clin Cancer Res,2009,15(2):692-700.
[27] FELDMAN E J,LANCET J E,KOLITZ J E,et al.First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia[J].J Clin Oncol,2011,29(8):979-985.
[28] FELDMAN E J,KOLITZ J E,TRANG J M,et al.Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin,in patients with advanced leukemia[J].Leukemia Res,2012,36(10):1283-1289.
[29] NIKANJAM M,CAPPARELLI E V,LANCET J E,et al.Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351:population pharmacokinetic assessment[J].Cancer Chemother Pharmacol,2018,81(1):171-178.
[30] ZUCKER D,BARENHOLZ Y.Optimization of vincristine-topotecan combination:paving the way for improved chemotherapy regimens by nanoliposomes[J].J Control Release,2010,146(3):326-333.
[31] MACKAY J A,CHEN M N,MCDANIEL J R,et al.Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection[J].Nat Mater,2009,8(12):993-999.
[32] FONG C W.Platinum anti-cancer drugs:free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect[J].Free Radic Biol Med,2016,95:216-229.
[33] RUTTALA H B,RAMASAMY T,GUPTA B,et al.Multiple polysaccharide-drug complex-loaded liposomes:a unique strategy in drug loading and cancer targeting[J].Carbohydr Polym,2017,173(1):57-66.
[34] 范晓慧.紫杉醇阿霉素共载药胶束的制备及体内外评价[D].济南:山东大学,2016.
[35] LIU Y R,FANG J X,KIM Y J,et al.Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity[J].Mol Pharm,2014,11(5):1651-1661.
[36] JIANG T Y,MO R,BELLOTI A,et al.Gel-liposome-mediated co-delivery of anticanacer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy[J].Adv Func Mater,2014,24(16):2295-2304.
[37] CHENG Y,ZHAO P X,WU S P,et al.Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma[J].Int J Pharm,2018,545(1):261-273.
[38] MONTAZERI M,SADEGHIZADEH M,PILEHVAR-SOLTANAHMADI Y,et al.Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines[J].Int J Pharm,2016,509(1):244-254.
[39] 杨建苗,李天傲,许东航.多柔比星-五味子乙素共载脂质体克服多药耐药的机制研究[J].中国现代应用药学,2017,34(12):1679-1682.
[40] 于跃,王军飞,王长云,等.抗多药耐药紫杉烷类抗肿瘤药物研究进展[J].中国现代应用药学,2012,29(1):16-23.
[41] KONG F,ZHANG X,ZHANG H,et al.Inhibition of multidrug resistance of cancer cells by co-delivery of dna nanostructures and drugs using porous silicon nanoparticles@giant liposomes[J].Adv Funct Mater,2015,25(22):3330-3340.
[42] CHEN Y,CHENG Y,ZHAO P X,et al.Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance[J].Int J Pharm,2018,542(1):266-279.
[43] ANREDDY N,GUPTA P,KATHAWALA J R,et al.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance[J].Molecules,2014,19(9):13848-13877.
[44] DENG Z J,MORTON S W,BEN-AKIVA E,et al.Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment[J].ACS Nano,2013,7(11):9571-9584.
[45] QU M H,ZENG R F,FANG S,et al.Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer[J].Int J Pharm,2014,474(1/2):112-122.
[46] REDDY T L,GARIKAPATI K R,REDDY S G,et al.Simultaneous delivery of paclitaxel and Bcl-2 siRNA via pH-sensitive liposomal nanocarrier for the synergistic treatment of melanoma[J].Sci Rep,2016,6:35223.
[47] DANHIER F,FERON O,PREAT V.To exploit the tumor microenvironment:passive and active tumor targeting of nanocarriers for anti-cancer drug delivery[J].J Control Release,2010,148(2):135-146.
[48] KHAWAR I A,KIM J H,KUH H J.Improving drug delivery to solid tumors:priming the tumor microenvironment[J].J Control Release,2015,201(10):78-89.
[49] SUN Y.Tumor microenvironment and cancer therapy resistance[J].Cancer Lett,2016,380(1):205-215.
[50] MO R,GU Z.Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery[J].Mater Today,2016,19(5):274-283.
[51] JI T J,LI S P,ZHANG Y L,et al.An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer[J].ACS Appl Mater Interfaces,2016,8(5):3438-3445.
[52] LV Y Q,XU C R,ZHAO X M,et al.Nanoplatform assembled from a cd44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells[J].ACS Nano,2018,12(2):1519-1536.
[53] KIM J M,CHEN D S.Immune escape to PD-L1/PD-1 blockade:seven steps to success(or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[54] BYUN D J,WOLCHOK J D,ROSENBERG L M,et al.Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J].Nat Rev Endocrinol,2017,13(4):195-207.
[55] YOON H Y,SELVAN S T,YANG Y,et al.Engineering nanoparticle strategies for effective cancer immunotherapy[J/OL].[2018-04-21].Biomaterials,2018,https://doi.org/10.1016/j.biomaterials.2018.03.036.
[56] TENG F F,MENG X J,KONG L,et al.Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy:a systematic review[J].Cancer Lett,2018,414:166-173.
[57] SHARMA P,HU-LIESKOVAN S,WARGO J A,et al.Primary,adaptive,and acquired resistance to cancer immunotherapy[J].Cell,2017,168(4):707-723.
[58] LIANG R J,XIE J,LI J,et al.Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response[J].Biomaterials,2017,149:41-50.


 REN Wen-xia,LI Jian-ke.Preparation and quality evaluation of tea polyphenol liposomes by reverse-phase evaporation[J].Chinese Journal of Bioprocess Engineering,2009,7(05):68.


基金项目:国家自然科学基金(81673381); 江苏省自然科学基金杰出青年基金(BK20150029)
作者简介:王梦玥(1993—),女,辽宁本溪人,硕士研究生,研究方向:药用功能材料与靶向递药系统; 蒋曙光(联系人),副教授,E-mail:cpujsg@163.com; 莫然(联系人),教授,E-mail:rmo@cpu.edu.cn
WANG Mengyue,LI Teng,JIANG Shuguang,et al.Recent advances in liposome-based co-delivery systems for combination cancer therapy[J].Chin J Bioprocess Eng,2018,16(5):33-41..
更新日期/Last Update: 2018-09-30